How effective is the Johnson & Johnson vaccine according to Johnson & Johnson
Questions about the efficacy, duration of protection and booster of the single-dose vaccine? Here's what Johnson & Johnson answers
“Johnson & Johnson is aware that data is circulating which can be confusing. We want to be sure that the most reliable and complete series of data on the effectiveness of our vaccine is understood ”, reads the press release issued by the company and reported by Borsa Italiana .
THE CLARIFICATION OF J&J
“More and more robust evidence – the company explains – supports a vaccination program with an authorized vaccine that provides benefits to people based on the risks associated with Covid-19. The data demonstrate that the Johnson & Johnson vaccine provides protection when given as a single dose for an effective response in times of pandemic emergency. When a booster dose of the J&J vaccine is administered, the strength of the protection increases, especially against symptomatic positives ”.
THE RESULTS OF THE STUDY BY J&J
Clinical studies, according to the multinational company, have shown 75% efficacy against severe / critical forms of Covid-19 with a single dose, and 100% after a second dose.
“In our large Phase 3 Ensemble clinical trial, a single dose of the Johnson & Johnson Covid-19 vaccine provided up to 75% overall efficacy against severe / critical Covid-19 after at least 28 days post vaccination. Furthermore, our Phase 3 Ensemble 2 study found that a second dose administered 56 days after the first dose provided 100% protection against severe / critical forms of Covid-19 at least 14 days after the first dose. 'last vaccination ".
The evidence in clinical practice, added J&J, showed an efficacy of 81% against Covid-related hospitalizations and "data from the Real World Evidence (Rwe) study previously announced by the Company showed estimates of vaccine efficacy. similar to those observed in our randomized clinical trials ".
Additionally, J&J points out, efficacy estimates remained stable and there was no evidence of diminished efficacy over time either before the Delta variant emerged or after it became the dominant strain in the US from March to August. "These results – the company clarifies – are also consistent with the studies on effectiveness against Covid-19 infections conducted by other bodies".
J&J VACCINE STUDIES NOT CARRIED OUT BY J&J
"Clinical practice", reports the Dire agency quoting the words of J&J, "includes studies published by the CDC (60% -84%, United States), the Janssen-Aetion study (81%, United States), the Sisonke ( 67% -71%, South Africa), the Dutch Ministry of Health General Population Study (91%, Netherlands) and the New York State General Population Study (85.5-82.8%, United States) on the effectiveness of the vaccine against hospitalization. All the methodologies are different and do not always demonstrate a complete picture of effectiveness ”.
WHAT J&J WILL DO NOW
The multinational has recently announced that it will submit to the European Medicines Agency (EMA) the authorization request for a complete package that includes the single dose plus a booster dose and no longer just a dose, as is now foreseen.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/quanto-e-efficace-il-vaccino-johnson-johnson-secondo-johnson-johnson/ on Wed, 17 Nov 2021 13:43:28 +0000.